These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 33497027)
41. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). Kolstad KD; Li S; Steen V; Chung L; Chest; 2018 Oct; 154(4):862-871. PubMed ID: 29777655 [TBL] [Abstract][Full Text] [Related]
42. Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension. Sanges S; Guerrier T; Duhamel A; Guilbert L; Hauspie C; Largy A; Balden M; Podevin C; Lefèvre G; Jendoubi M; Speca S; Hachulla É; Sobanski V; Dubucquoi S; Launay D Front Immunol; 2022; 13():954007. PubMed ID: 35967377 [TBL] [Abstract][Full Text] [Related]
43. Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions. Erdogan M; Kilickiran Avci B; Ebren C; Ersoy Y; Ongen Z; Ongen G; Hamuryudan V; Hatemi G Clin Exp Rheumatol; 2024 Aug; 42(8):1590-1597. PubMed ID: 38489342 [TBL] [Abstract][Full Text] [Related]
44. Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension. Corrado A; Correale M; Mansueto N; Monaco I; Carriero A; Mele A; Colia R; Di Biase M; Cantatore FP Microvasc Res; 2017 Nov; 114():46-51. PubMed ID: 28619664 [TBL] [Abstract][Full Text] [Related]
45. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686 [TBL] [Abstract][Full Text] [Related]
47. Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations. Thakkar V; Patterson KA; Stevens W; Wilson M; Roddy J; Sahhar J; Proudman S; Hissaria P; Nikpour M Clin Rheumatol; 2018 Jun; 37(6):1563-1571. PubMed ID: 29687288 [TBL] [Abstract][Full Text] [Related]
48. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Chung L; Domsic RT; Lingala B; Alkassab F; Bolster M; Csuka ME; Derk C; Fischer A; Frech T; Furst DE; Gomberg-Maitland M; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Silver R; Simms R; Varga J; Gordon JK; Steen VD Arthritis Care Res (Hoboken); 2014 Mar; 66(3):489-95. PubMed ID: 23983198 [TBL] [Abstract][Full Text] [Related]
49. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Lip PL; Chatterjee S; Caine GJ; Hope-Ross M; Gibson J; Blann AD; Lip GY Br J Ophthalmol; 2004 Dec; 88(12):1543-6. PubMed ID: 15548809 [TBL] [Abstract][Full Text] [Related]
50. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A; Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119 [TBL] [Abstract][Full Text] [Related]
51. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis. Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265 [TBL] [Abstract][Full Text] [Related]
52. Severe Pulmonary Arterial Hypertension Is Characterized by Increased Neutrophil Elastase and Relative Elafin Deficiency. Sweatt AJ; Miyagawa K; Rhodes CJ; Taylor S; Del Rosario PA; Hsi A; Haddad F; Spiekerkoetter E; Bental-Roof M; Bland RD; Swietlik EM; Gräf S; Wilkins MR; Morrell NW; Nicolls MR; Rabinovitch M; Zamanian RT Chest; 2021 Oct; 160(4):1442-1458. PubMed ID: 34181952 [TBL] [Abstract][Full Text] [Related]
53. Prognostic factors of mortality and 2-year survival analysis of systemic sclerosis with pulmonary arterial hypertension in Thailand. Foocharoen C; Nanagara R; Kiatchoosakun S; Suwannaroj S; Mahakkanukrauh A Int J Rheum Dis; 2011 Aug; 14(3):282-9. PubMed ID: 21816025 [TBL] [Abstract][Full Text] [Related]
54. Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor β in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Stefanantoni K; Sciarra I; Vasile M; Badagliacca R; Poscia R; Pendolino M; Alessandri C; Vizza CD; Valesini G; Riccieri V Reumatismo; 2015 Mar; 66(4):270-6. PubMed ID: 25829187 [TBL] [Abstract][Full Text] [Related]
55. Disturbed balance between serum levels of receptor tyrosine kinases Tie-1, Tie-2 and angiopoietins in systemic sclerosis. Gerlicz Z; Dziankowska-Bartkowiak B; Dziankowska-Zaborszczyk E; Sysa-Jedrzejowska A Dermatology; 2014; 228(3):233-9. PubMed ID: 24603462 [TBL] [Abstract][Full Text] [Related]
56. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease. Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031 [TBL] [Abstract][Full Text] [Related]
57. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055 [TBL] [Abstract][Full Text] [Related]
58. Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme. Morrisroe K; Stevens W; Sahhar J; Rabusa C; Nikpour M; Proudman S; Arthritis Res Ther; 2017 Mar; 19(1):42. PubMed ID: 28270192 [TBL] [Abstract][Full Text] [Related]
59. Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Allanore Y; Borderie D; Lemaréchal H; Ekindjian OG; Kahan A Arthritis Res Ther; 2004; 6(4):R309-14. PubMed ID: 15225366 [TBL] [Abstract][Full Text] [Related]
60. Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients. Romaniello A; Rubattu S; Gigante A; Simonelli F; Grimaldi MC; D'Angelo A; Alunni D; Sada L; Gasperini ML; Marchitti S; Volpe M; Rosato E J Cardiovasc Med (Hagerstown); 2019 Nov; 20(11):771-779. PubMed ID: 31397686 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]